RedirecTT-1: Dual antigen-targeting treatment associated with promising efficacy in EMD myeloma

The combination of talquetamab and teclistamab was associated with deep and durable responses in patients with true extramedullary (EMD) myeloma. According to the researchers, the displayed efficacy of the treatment in this study exceeds standard therapies and novel T-cell-redirecting therapies. Talquetamab targets a G protein-coupled receptor (GPRC5D), and teclistamab targets B-cell maturation antigen (BCMA). The phase 2 RedirecTT-1 study (NCT04586426) tested the combination of these two agents in patients with true EMD myeloma (n=90) [1]. The primary endpoint was the overall response rate (ORR). “All patients were triple-class refractory and the majority of them had received at least 5 prior therapies (56.7%),” added Dr Shaji Kumar (Mayo Clinic, MN, USA). The ORR was 78.9%, and 54.4% of the participants achieved at least a complete response. These rates were ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 June 20252 September 2025